These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 11459867)

  • 1. Blocking oncogenic Ras signaling for cancer therapy.
    Adjei AA
    J Natl Cancer Inst; 2001 Jul; 93(14):1062-74. PubMed ID: 11459867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Re: Blocking oncogenic Ras signaling for cancer therapy.
    Canevari S; Biocca S; Figini M
    J Natl Cancer Inst; 2002 Jul; 94(13):1031-2; author reply 1032. PubMed ID: 12096090
    [No Abstract]   [Full Text] [Related]  

  • 3. Ras signaling pathway proteins as therapeutic targets.
    Adjei AA
    Curr Pharm Des; 2001 Nov; 7(16):1581-94. PubMed ID: 11562300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of the ras oncogene as therapeutic targets.
    Ghobrial IM; Adjei AA
    Hematol Oncol Clin North Am; 2002 Oct; 16(5):1065-88. PubMed ID: 12512383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Agents targeting ras signaling pathway.
    Dancey JE
    Curr Pharm Des; 2002; 8(25):2259-67. PubMed ID: 12369854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Ras prenylation: a signaling target for novel anti-cancer drug design.
    Lerner EC; Hamilton AD; Sebti SM
    Anticancer Drug Des; 1997 Jun; 12(4):229-38. PubMed ID: 9199657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of ras oncogene: a novel approach to antineoplastic therapy.
    Scharovsky OG; Rozados VR; Gervasoni SI; Matar P
    J Biomed Sci; 2000; 7(4):292-8. PubMed ID: 10895051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Ras prenylation: a novel approach to cancer chemotherapy.
    Sebti SM; Hamilton AD
    Pharmacol Ther; 1997; 74(1):103-14. PubMed ID: 9336018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ras family signaling: therapeutic targeting.
    Cox AD; Der CJ
    Cancer Biol Ther; 2002; 1(6):599-606. PubMed ID: 12642680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ras farnesyltransferase inhibition: a novel and safe approach for cancer chemotherapy.
    Nammi S; Lodagala DS
    Acta Pharmacol Sin; 2000 May; 21(5):396-404. PubMed ID: 11324435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ras as a target in cancer therapy.
    Midgley RS; Kerr DJ
    Crit Rev Oncol Hematol; 2002 Nov; 44(2):109-20. PubMed ID: 12413630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development.
    Rowinsky EK; Windle JJ; Von Hoff DD
    J Clin Oncol; 1999 Nov; 17(11):3631-52. PubMed ID: 10550163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. K-Ras and its inhibitors towards personalized cancer treatment: Pharmacological and structural perspectives.
    Asati V; Mahapatra DK; Bharti SK
    Eur J Med Chem; 2017 Jan; 125():299-314. PubMed ID: 27688185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells.
    Morgan MA; Sebil T; Aydilek E; Peest D; Ganser A; Reuter CW
    Br J Haematol; 2005 Sep; 130(6):912-25. PubMed ID: 16156861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?
    Cox AD; Der CJ
    Biochim Biophys Acta; 1997 Aug; 1333(1):F51-71. PubMed ID: 9294018
    [No Abstract]   [Full Text] [Related]  

  • 17. Cdc42 Signaling Pathway Inhibition as a Therapeutic Target in Ras- Related Cancers.
    Aguilar BJ; Zhou H; Lu Q
    Curr Med Chem; 2017; 24(32):3485-3507. PubMed ID: 28571533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice.
    Liu M; Bryant MS; Chen J; Lee S; Yaremko B; Li Z; Dell J; Lipari P; Malkowski M; Prioli N; Rossman RR; Korfmacher WA; Nomeir AA; Lin CC; Mallams AK; Doll RJ; Catino JJ; Girijavallabhan VM; Kirschmeier P; Bishop WR
    Cancer Chemother Pharmacol; 1999; 43(1):50-8. PubMed ID: 9923541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of the immune response and tumor growth by activated Ras.
    Weijzen S; Velders MP; Kast WM
    Leukemia; 1999 Apr; 13(4):502-13. PubMed ID: 10214854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RAS and leukemia: from basic mechanisms to gene-directed therapy.
    Beaupre DM; Kurzrock R
    J Clin Oncol; 1999 Mar; 17(3):1071-9. PubMed ID: 10071302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.